pharmafile | October 28, 2003 | News story | Research and Development |Â Â Â
Breast Cancer Now commits £800,000 to AI research into late breast cancer recurrence
AstraZeneca’s Trixeo approved in EU for asthma in patients aged 12 and over
Acumentis CEO Herspiegel steps down as Burden assumes role
Sobi’s olezarsen recommended for EU approval in severe hypertriglyceridaemia
Hot-tub therapy tested as potential treatment for peripheral artery disease